SYDNEY, Australia, Oct. 3 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS, NASDAQ: PXSL) has announced that researchers will present 12 abstracts from its respiratory disease program at the 2008 European Respiratory Society Congress (ERS) being held in Berlin from the 4th to the 8th October. The ERS brings together many of the world's top respiratory researchers and clinicians to hear latest advances in clinical diagnosis and treatment.
A comprehensive program of research will be presented in ERS symposiums and poster sessions relating to the lung challenge product, Aridol, and the mucus clearing agent, Bronchitol.
In a poster session Professor Di Bilton, Consultant Physician and Honorary Senior Lecturer at the Department of Respiratory Medicine, The Royal Brompton Hospital, London, UK, will detail results of a successful randomized, placebo- controlled trial of inhaled mannitol (Bronchitol) in patients with bronchiectasis.
Other key ERS program events from the Pharmaxis respiratory disease
-- The use of inhaled mannitol (Aridol) for assessing airway disease
-- Direct versus indirect airway challenges
-- Using a dry powder of mannitol (Aridol) versus methacholine as
challenge for routine practice
-- Inhaled mannitol (Bronchitol) as treatment for children with cystic
-- Implications for everyday practice
-- Infectious lung diseases including tuberculosis
-- A randomized, placebo-controlled trial of inhaled
mannitol(Bronchitol) in patients with bronchiectasis
-- Cough and airway hyperresponsiveness
-- A comparison of inhaled mannitol (Aridol), methacholine
provocation and eucapnic voluntary hyperventilation as diagnostic
tests for exercised-induced bronchoconstriction in cross country
-- Assessment of inflamm
Copyright©2008 PR Newswire.
All rights reserved